IDXX Stock Analysis — Idexx Laboratories
Sector: Healthcare
AI Verdict
Idexx is expensive for the growth on offer, so you’re paying up for the moat of sticky veterinary customers and must believe that growth will keep outpacing the sector.
Competitive Moat
Idexx Laboratories dominates the global veterinary diagnostics market with proprietary testing platforms and a vast installed base in animal hospitals, creating high switching costs for clinics. Its recurring revenue from consumables and exclusive distribution relationships reinforce its defensibility.
Summary
Idexx is notable right now for its premium valuation on steady veterinary diagnostics growth and entrenched customer relationships.
Where It Stands
Idexx has returned 3.99% over the past year, trades at 34.9x next year's earnings (well above the healthcare sector median of 22x), and its RSI of 46.2 signals neutral momentum.
Key Metrics
- RSI: 46.2 — Neutral
- Trailing P/E: 41.1x
- Forward P/E: 34.9x
- PEG Ratio: 2.10
- Earnings Growth: +0.2%
- Revenue Growth: +0.1%
- Market Cap: $44.3B
- 1-Year Return: 3.99%
- 52-Week High: $769.98
- 52-Week Low: $506.91
Analyst Consensus
14 Buy · 8 Hold · 0 Sell (22 analysts)
Bull Case
You are paying 34.9x forward earnings for 17.9% expected EPS growth, which is a rare combination in healthcare diagnostics.
Bear Case
If the P/E compresses from 34.9x to the sector median of 22x, the stock could lose over a third of its value even if earnings hit targets.
Catalyst to Watch
Watch for quarterly earnings updates—any slowdown in EPS growth below the 17.9% consensus would likely trigger a sharp rerating.